CollPlant, a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, announced it filed a patent application in the United States for bio-ink based on rhCollagen for three-dimensional printing of tissues and organs.
“The patent application is a part of the company’s strategy to establish its position as a leader in 3D bio-printing, and as a basis for collaborations with leading companies in the field of organ printing, in which CollPlant will constitute the biological ink supplier, in various formulations,” said CollPlant in a statement.
“The patent application refers to formulations of biological ink based on recombinant human collagen, which is an ideal building block for bio-ink.
“CollPlant’s bio-ink enables the printing of three-dimensional scaffolds combined with human cells and/or growth factors as a basis for tissue or organ formation.
“In addition to the collagen, CollPlant’s bio-ink formulations can include other proteins and/or polymers, they are compatible with various 3D bio-printing technologies, and to the printed organ characteristics.”
CollPlant CEO Yehiel Tal said: “We are promoting commercial collaborations with leading international companies in the field of 3D bio-printing of tissue and organ, with the aim of taking part in providing a solution to the significant need for life saving organs.
“This market need represents high economic potential for the company.
“The new patent establishes CollPlant’s technology status in 3D biological printing, creates barriers to entry for competitors and increases the trust of potential partners.
“CollPlant’s technology is highly regarded by major international players, and our objective is to enter into our first significant collaboration this year.”